Change in Ypsomed leadership

Burgdorf, (PresseBox) - The Ypsomed Group accomplished its turnaround in fiscal year 2013-2014 and is well-placed in all business areas. For this reason, board president and CEO Willy Michel has decided to focus on his role as president and delegate of the board in the future. The board of directors of the Ypsomed Group has unanimously elected his son Simon Michel as successor today. Simon Michel has been a member of the executive board of the Ypsomed Group since 2008 and has, until now, been responsible for the Marketing & Sales area. He will take over his new role on July 1, 2014. Comprehensive information on the CEO change will be announced during the financial press conference on May 27, 2014.

Ypsomed AG

The Ypsomed Group is a leading, independent Swiss developer and manufacturer of injection systems for selfmedication and a renowned diabetes specialist with over 25 years of experience. Founded in 2003 from the wellknown company Disetronic, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field.

Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements;

contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,000 employees.

Press releases you might also be interested in

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.